Modification of gene activity in mouse embryos in utero by a tamoxifen-inducible form of Cre recombinase

被引:1074
作者
Danielian, PS
Muccino, D
Rowitch, DH
Michael, SK
McMahon, AP
机构
[1] Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA
[2] Inst Canc Res, Chester Beatty Labs, London SW3 6JB, England
关键词
D O I
10.1016/S0960-9822(07)00562-3
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The ability to generate specific genetic modifications in mice provides a powerful approach to assess gene function. When genetic modifications have been generated in the germ line, however, the resulting phenotype often only reflects the first time a gene has an influence on - or is necessary for - a particular biological process. Therefore, systems allowing conditional genetic modification have been developed (for a review, see [1]); for example, inducible forms of the Cre recombinase from pi phage have been generated that can catalyse intramolecular recombination between target recognition sequences (loxP sites) in response to ligand [2-5]. Here, we assessed whether a tamoxifen-inducible form of Cre recombinase (Cre-ERTM) could be used to modify gene activity in the mouse embryo in utero, Using the enhancer of the Wnt1 gene to restrict the expression of Cre-ERTM to the embryonic neural tube, we found that a single injection of tamoxifen into pregnant mice induced Cre-mediated recombination within the embryonic central nervous system, thereby activating expression of a reporter gene. Induction was ligand dependent, rapid and efficient. The results demonstrate that tamoxifen-inducible recombination can be used to effectively modify gene function in the mouse embryo. (C) Current Biology Ltd ISSN 0960-9822.
引用
收藏
页码:1323 / 1326
页数:4
相关论文
共 15 条
[1]   Spatio-temporally controlled site-specific somatic mutagenesis in the mouse [J].
Brocard, J ;
Warot, X ;
Wendling, O ;
Messaddeq, N ;
Vonesch, JL ;
Chambon, P ;
Metzger, D .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (26) :14559-14563
[2]   IDENTIFICATION OF RESIDUES IN THE ESTROGEN-RECEPTOR THAT CONFER DIFFERENTIAL SENSITIVITY TO ESTROGEN AND HYDROXYTAMOXIFEN [J].
DANIELIAN, PS ;
WHITE, R ;
HOARE, SA ;
FAWELL, SE ;
PARKER, MG .
MOLECULAR ENDOCRINOLOGY, 1993, 7 (02) :232-240
[3]  
ECHELARD Y, 1994, DEVELOPMENT, V120, P2213
[4]   CHARACTERIZATION AND COLOCALIZATION OF STEROID BINDING AND DIMERIZATION ACTIVITIES IN THE MOUSE ESTROGEN-RECEPTOR [J].
FAWELL, SE ;
LEES, JA ;
WHITE, R ;
PARKER, MG .
CELL, 1990, 60 (06) :953-962
[5]   Ligand-activated site-specific recombination in mice [J].
Feil, R ;
Brocard, J ;
Mascrez, B ;
LeMeur, M ;
Metzger, D ;
Chambon, P .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (20) :10887-10890
[6]   ENDOCRINE PHARMACOLOGY OF ANTIESTROGENS AS ANTITUMOR AGENTS [J].
JORDAN, VC ;
MURPHY, CS .
ENDOCRINE REVIEWS, 1990, 11 (04) :578-610
[7]   Regulation of cre recombinase activity by the synthetic steroid RU 486 [J].
Kellendonk, C ;
Tronche, F ;
Monaghan, AP ;
Angrand, PO ;
Stewart, F ;
Schutz, G .
NUCLEIC ACIDS RESEARCH, 1996, 24 (08) :1404-1411
[8]  
Lee SMK, 1997, DEVELOPMENT, V124, P959
[9]   A MODIFIED ESTROGEN-RECEPTOR LIGAND-BINDING DOMAIN AS AN IMPROVED SWITCH FOR THE REGULATION OF HETEROLOGOUS PROTEINS [J].
LITTLEWOOD, TD ;
HANCOCK, DC ;
DANIELIAN, PS ;
PARKER, MG ;
EVEN, GI .
NUCLEIC ACIDS RESEARCH, 1995, 23 (10) :1686-1690
[10]  
MATTIONI T, 1994, METHOD CELL BIOL, V43, P335